February 15, 2019

February 15, 2019

Gary Aubuchon to ride for Cure on Wheels

Fort Myers Beach Observer – Feb. 15

The ride will begin at the Moffitt Cancer Center in Tampa to the steps of the Capital Building in Tallahassee. Aubuchon will travel the distance on his 1997 Schwinn Passage.



Neuroendocrine Tumors: Combo Therapies Usually Beat Single Agents

Medpage Today – Feb. 14

In an accompanying editorial, Jonathan Raphael Strosberg, MD, of the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida, and colleagues, pointed out that Walter's group had more challenges to overcome when interpreting the literature than for most other cancers.


Amy Scherzer’s Diary: Weekly Wrap-Up of the Tampa Social Scene

Tampa Bay Times – Feb. 14

The adjectives just kept coming — driven, determined, doggone stubborn — when Preserve Vision Florida named H. Lee Moffitt its 2019 Person of Vision at its 40th anniversary dinner for leadership launching the cancer center that bears his name. Six “toasters”— Doretha Edgecomb, Judy Lisi, Betty Castor, Sam Bell, Rep. James Grant and Dr. Alan List — spoke for the whole Moffitt fan club Feb. 11 at the Hilton Downtown Tampa. 


Q&A with NaplesNEXT Chef 

Gulfshore Life – February 2019

The three-day program at the Naples Grande Beach Resort is jam-packed with more than 40 speakers and talent from the most influential corners of our country, from First Lady Laura Bush to former CIA director John Brennan to the editor-in-chief of National Geographic to the radiology department chair at Moffitt Cancer Center to the president and CEO of the Boston Red Sox. 


Power in Numbers

Cure – Feb. 13

Factors such as age and heart and lung function help determine a patient’s eligibility for the procedure, says Kenneth Shain, M.D., Ph.D., a myeloma specialist in the departments of malignant hematology and tumor biology at Moffitt Cancer Center in Florida.


Anixa Biosciences to Present at Moffitt Cancer Center's Business of Biotech Conference

PR Newswire – Feb. 13

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that Dr. Amit Kumar, its President and CEO, will be presenting on a panel discussion at Moffitt Cancer Center's 13th Annual Business of Biotech Conference being held on February 22, 2019.  


Cancer Cure: Israeli Biotech Company Claims It Can Offer Remedy For This Lethal Disease

Business Times – Feb. 13

Vince C. Luca, Ph.D., principal investigator in drug discovery at the Moffitt Cancer Center said, "There are over 200 human cancers" recorded at present, among all these kinds "finding a cure for even one or two would be a major accomplishment. Claiming to cure them all is impossible."


Specialist says tobacco addiction caused man’s death in Philip Morris trial

Florida Record – Feb. 12
Rosen called his first witness, Dr. David J. Drobes, a specialist in the psychology of nicotine addiction with the Moffitt Cancer Center in Tampa. Drobes coordinates a research lab at the facility that develops treatments to help people quit smoking through research and intervention programs.


Vincent House honors John Morroni for his courage

Tampa Bay Newspapers – Feb. 12
He held his 23rd annual event Feb. 21, 2018. The event raised $80,000 for Moffitt Cancer Center Foundation. At the time, Morroni didn’t know it would only be a couple months before he returned to Moffitt for his final battle with cancer.


Florida House takes first stab at repeal of medical marijuana smoking ban

Bradenton Herald – Feb. 12

Dr. Thomas Sellers, the center director of Moffitt Cancer Center in Tampa, said while their research group has been active and committed, a total lack of funding meant they were only able to conduct two small studies over the course of six months.


Moffitt Cancer Center secures radiology machines by ditching anti-virus software

HealthCare Business News Magazine – Feb. 12

The machines that interpret radiology scans and other medical images at Moffitt Cancer Center are regular Windows-based workstations running GE-PACS. 


Luspatercept May Reduce the Need for Transfusion in Lower-Risk Myelodysplastic Syndromes

ASCO Post – Feb. 10

With luspatercept, 37.9% remained transfusion-free for 8 weeks or longer, compared with 13.2% treated with placebo, according to Alan List, MD, of Moffitt Cancer Center, Tampa, who presented the findings at the Plenary Session during the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition.


Little Greek President Alive Thanks To Bone Marrow Donor

Patch – Feb. 11

Two years after his bone marrow transplant, Vojnovic completes the Miles for Moffitt race in December to benefit the H. Lee Moffitt Cancer Center & Research Institute.


Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.